While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.